747414-18-2

Basic information

• Product Name: Ethanone, 1-[5-(1-Methylethyl)-2,4-bis(phenylMethoxy)phenyl]-
• Synonyms: Ethanone, 1-[5-(1-Methylethyl)-2,4-bis(phenylMethoxy)phenyl]-;1-(2,4-bis(benzyloxy)-5-isopropylphenyl)ethanone;1-(2,4-bis(benzyloxy)-5-isopropylphenyl)ethan-1-one
• CAS NO: 747414-18-2
• Molecular Formula: C₂₅H₂₆O₃
• Molecular Weight: 374.47214
• Mol File: 747414-18-2.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ethanone, 1-[5-(1-Methylethyl)-2,4-bis(phenylMethoxy)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-[5-(1-Methylethyl)-2,4-bis(phenylMethoxy)phenyl]-(747414-18-2)
• EPA Substance Registry System: Ethanone, 1-[5-(1-Methylethyl)-2,4-bis(phenylMethoxy)phenyl]-(747414-18-2)

Safety Data

• Hazardous Substances Data: 747414-18-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Ethanone, 1-[5-(1-Methylethyl)-2,4-bis(phenylMethoxy)phenyl]is utilized as a key intermediate in organic synthesis for the creation of a variety of chemical compounds. Its unique structure allows for versatile reactions and the formation of new molecules with potential applications in various fields.
Used in Pharmaceutical Research:
In the pharmaceutical industry, Ethanone, 1-[5-(1-Methylethyl)-2,4-bis(phenylMethoxy)phenyl]is employed as a starting material or a building block in drug development. Its potential medicinal properties make it a candidate for the synthesis of new pharmaceuticals, particularly those targeting specific biological pathways or diseases.
Used in Academic Research:
Ethanone, 1-[5-(1-Methylethyl)-2,4-bis(phenylMethoxy)phenyl]is also of interest in academic research, particularly in the fields of organic chemistry and chemical biology. Its complex structure provides a platform for studying reaction mechanisms, exploring new synthetic routes, and understanding the relationship between molecular structure and biological activity.
Used in Specialty Chemicals and Materials Production:
Due to its unique properties, Ethanone, 1-[5-(1-Methylethyl)-2,4-bis(phenylMethoxy)phenyl]may also find applications in the production of specialty chemicals and materials. These could include high-performance materials for various industries, such as electronics, coatings, or advanced materials for specific technical applications.

Upstream product

• 22877-01-6 2,4-bis(benzyloxy)acetophenone 
• 23504-03-2 2,4-dihydroxy-1-isopropylbenzene 
• 747414-16-0 (((4-(prop-1-en-2-yl)-1,3-phenylene)bis(oxy))bis(methylene))dibenzene 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 747414-17-1 1-(2,4-dihydroxy-5-isopropylphenyl)ethan-1-one 
• 100-39-0 benzyl bromide 

Downstream Products

• 943519-38-8 2,4-bisbenzyloxy-5-isopropylbenzoic acid methyl ester 

Relevant articles and documents

An HSP90 inhibitor based fluorescent probe for selective tumor targeting

Fluorescent imaging has been widely used in the detection of diseases, especially cancer. Among them, biomarker-specific ligand-based imaging strategies have attracted much attention, due to their improved image contrast and diagnostic accuracy. In this w

2, 4-diaminopyrimidine compound containing phenol fragment, preparation method, pharmaceutical compositions and use thereof

The invention discloses a 2, 4-diaminopyrimidine compound containing phenol fragment with a general formula I shown in the specification, pharmaceutically acceptable salts or pharmaceutically acceptable solvates, a preparation method thereof, pharmaceutical compositions containing the compounds, and use of the compounds in preparation of drugs for preventing or treating anaplastic lymphoma kinaserelated abnormal cell proliferation, morphological changes, hyperkinesia and other associated diseases in organisms, and angiogenesis or cancerometastasis associated diseases, especially use in drugsfor treating or preventing tumor growth and metastasis.

4,5-diphenyl isoxazole derivative as well as preparation method and application thereof

The invention discloses a 4,5-diphenyl isoxazole derivative as well as a preparation method and application thereof. Specifically, the invention relates to a 4,5-diphenyl isoxazole derivative of a structure represented by the formula (I), a stereoisomer or pharmaceutically acceptable salt of the derivative, wherein the definition of each substituent in the formula (I) is the same as that in a specification. Compounds of novel structures have the activity of inhibiting heat shock proteins HSP90, can be used for treating cancers, neurodegenerative diseases, inflammatory diseases, autoimmune diseases and ischemic brain injuries, and has wide application prospect.

Phenyl 1, 2 - isoxazole or phenyl 1, 2 - pyrazole compound and use thereof (by machine translation)

The invention discloses the following formula of phenyl 1, 2 - different oxazole or 1, 2 - pyrazole compounds with use. Through the biological activity tests show that, the compound inhibiting heat shock protein 90 activity. Therefore, the invention phenyl 1, 2 - different oxazole or 1, 2 - pyrazole compounds can be used as a heat shock protein 90 inhibitor for the treatment of cancer. (by machine translation)

Heat shock protein inhibitor and preparation method and application thereof

The present invention discloses a heat shock protein inhibitor and a preparation method and an application thereof, and belongs to the technical field of medicinal chemistry. The heat shock protein inhibitor has the structure features of a formula I. The compound can inhibit activity of the heat shock protein 90, and then can be used for preparing anti-tumor drugs.

Synthesis and biological evaluation of 3,5-disubstituted-4-alkynylisoxozales as a novel class of HSP90 inhibitors

Abstract A series of 3,5-disubstitute-4-alkynylisoxazole derivatives were designed and synthesized through palladium(II)-copper(I) catalyzed Sonogashira cross-coupling reaction of an alkynyl moiety and an isoxazole scaffold as novel HSP90 inhibitors. The resultant compounds displayed moderate to potent binding affinity to HSP90 proteins, and also demonstrated good cell growth inhibitory activity against various cancer cell lines (A549, K562, MCF-7, DU145 and Hela). Some compounds (18d, 18e, 19a, 19d, 20c and 20q) show similar or better binding affinity towards HSP90α and HSP90β comparing to NVP-AUY922. In addition, compounds 18e, 19a and 20q exhibited potent inhibitory activity against various human cancer cell lines.

Hybrids of the benzofuran core from natural products and the 2,4-dihydroxy-5-isopropylbenzene fragment as potent Hsp90 inhibitors: Design, synthesis and bioevaluation

Several chemical fragments have been confirmed as highly efficient cores for the design of Hsp90 inhibitors. Molecular hybridization of potent fragments has been widely used as a rational drug discovery strategy. In this study, a novel class of hybrids of benzofuran, a privileged core from natural products, and 2,4-dihydroxy-5-isopropyl phenyl, an efficient fragment in Hsp90 inhibitors, were designed and synthesized. Subsequent evaluation confirmed they inhibited cell proliferation and regulated the level of client proteins through Hsp90 inhibition. Some of the hybrids can serve as leads to obtain novel chemotypes of Hsp90 inhibitors. The methods reported here may expand the range of known structural types accommodated by the ATP binding site of Hsp90.

PHARMACEUTICAL COMPOUNDS

The invention provides a compound for use in medicine, the compound being a compound of the formula (VI0) or a salt, solvate, tautomer or N-oxide thereof: wherein the bicyclic group: is selected from the structures C1, C5 and C6: wherein n is 0, 1, 2 or 3; R1 is hydrogen, hydroxy, or O—Rz; R2a is hydroxy, methoxy or O—Rz; provided that at least one of R1 and R2a is O—Rz; Rz is Lp-Rp1; SO3H; a glucuronide residue; a mono-, di- or tripeptide residue; or Lp is a bond, C═O, (C═O)O, (C═O)NRp1 or S(O)xNRp1; x is 1 or 2; Rp1 is hydrogen or a an optionally substituted C1-25 hydrocarbyl group containing 0, 1 or 2 carbocyclic rings and 0, 1, 2, 3, 4, 5 or 6 carbon-carbon multiple bonds, provided that Rp1 is not hydrogen when Lp is a bond, C═O or (C═O)O; and provided also that O—Rz does not contain an O—O moiety; and excluding compounds wherein R1 is hydroxy and R2a is methoxy; Rp2 and Rp3 are the same or different and each is a group Rp1; and R3, R4a, R8 and R10 are defined in the claims. The compounds of formula (VI0) are pro-drugs of parent compounds wherein R1 and/or R2a are hydroxy, wherein the parent compounds have Hsp90 inhibiting activity.

HSP90 INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to HSP90 inhibitors containing a zinc binding moiety and their use in the treatment of cell proliferative diseases such as cancer. The said derivatives may further act as HDAC inhibitors.

4,5-Diarylisoxazole Hsp90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer

Inhibitors of the Hsp90 molecular chaperone are showing considerable promise as potential chemotherapeutic agents for cancer. Here, we describe the structure-based design, synthesis, structure - activity relationships and pharmacokinetics of potent small-molecule inhibitors of Hsp90 based on the 4,5-diarylisoxazole scaffold. Analogues from this series have high affinity for Hsp90, as measured in a fluorescence polarization (FP) competitive binding assay, and are active in cancer cell lines where they inhibit proliferation and exhibit a characteristic profile of depletion of oncogenic proteins and concomitant elevation of Hsp72. Compound 40f (VER-52296/NVP-AUY922) is potent in the Hsp90 FP binding assay (IC50 = 21 nM) and inhibits proliferation of various human cancer cell lines in vitro, with GI50 averaging 9 nM. Compound 40f is retained in tumors in vivo when administered i.p., as evaluated by cassette dosing in tumor-bearing mice. In a human colon cancer xenograft model, 40f inhibits tumor growth by ～50%.